ECTRIMS 2010 and CCSVI
Posted: Mon Nov 29, 2010 3:08 pm
..
Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. Join our friendly community of patients, caregivers, and researchers celebrating over 20 years of delivering hope through knowledge.
https://www.thisisms.com/forum/
http://www.mscrossfire.com/faculty.aspTimothy Vollmer's Disclosures:
Grant/Research Support: Acorda Therapeutics, BioMS Medical, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Genentech, Genzyme Corp, Novartis, Ono Pharmaceuticals, PDL BioPharma, Pfizer, Inc., Sanofi-Aventis, Teva Neuroscience
Consultant/Scientific Boards: Biogen Idec, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Glaxo SmithKline, IMPAX, Novartis, Xeroport
Speaker’s Bureau/Speaking Honoraria: Athena Diagnostics, Biogen Idec, Teva Neuroscience
WHY is CCSVI being discussed in the general forum now?Lyon wrote:Wow, are you intentionally giving me an awesome example of just how overpowering the conspiracy theory can become when allowed to run wild?cheerleader wrote:You're right, Bob. Why would Rocky Mountain MS Center, a medical center dedicated to helping those with MS, want to initiate a clinical trial that isn't paid for by pharma? Dr. Vollmer insists more clinical trials are needed for CCSVI, he runs an MS center with monetary resources and pwMS...but how can you make any more money studying venous function in MS? It's a problem.
cheer
First it has to be convincingly shown that there is something....ANYTHING to the CCSVI theory and maybe after that point would be a good time to spend the time, effort and of course MONEY trying to figure out why/how it works?
So we are still trying to deflect critiscm of CCSVI by claiming that anyone critical of CCSVI HAS TO have some ulterior motive. Could it be that Dr. Voller looked at the recent results of the CCSVI trials and concluded what he wrote above? You did not like someone assuming things about you so why do it to someone else?cheerleader wrote:Oh, he's very well connected! Here are a list of the clinical trials currently recruiting at Rocky Mountain MS Center--
Novartis (Informs)
Tysabri (stratify-2)
Copaxone/Estriol
Tysabri (Deliver)
http://www.mscenter.org/research/clinic ... -a-trials/
RMMS Center gets lots of contributions from individuals and foundations....why can't they initiate a study into cerebral perfusion and MS, or altitude, oxygen and MS, or venous return and MS? They've got the money.
My point is not that there is a grand conspiracy, but rather, someone like Dr. Vollmer who only conducts clinical trials which involve pharmaceuticals should not be so quick to write off an entire theory without further evidence. He also didn't refer to the ECTRIMS papers presented by BNAC, Simka or Zamboni.In addition to NO and cytokine mediated changes in cerebral perfusion, disturbed glial cell homeostasis may contribute to a heightened susceptibility for vascular changes in MS patients. Recently, it was reported that a rise of calcium levels within astrocytes induces constriction of blood vessels and consequently reduces cerebral blood flow [53]. The absence or reduction of astrocytic factors causes BBB endothelial cells to carry a reduced number of mitochondria. A decreased mitochondrial content in endothelial cells in MS postmortem tissue is hypothesized to be a primary event in the disruption of the BBB [54].
On the other hand, early vascular endothelial cell activation was identified prior to cerebral parenchymal reaction and demyelination [55], which, in combination with discrete microglial activation and perivascular cellular infiltrates, is a frequent finding in postmortem tissue of MS patients [56]. Microglial activation coincided with abnormal endothelial tight junctions in active lesions and normal appearing white matter, leading to putatively open junctions in microscopically inflamed vessels [57]. Future studies will have to prove whether and which vascular factors in MS patients may facilitate the inflammatory process, and whether vascular vulnerability in our patients is a prerequisite for the initiation of the autoimmune cascade.
http://www.denvermagazine.com/May-2010/ ... -Altitude/According to ARC director Ben Honigman, M.D., the center has two main focuses. First is the study of integrative physiology, how hypoxia affects the whole person as well as at cellular and molecular levels. This includes the search for a prevention and cure for AMS — which could have implications both economic and military. Investigators are also identifying specific genes that can predict who will get sick and studying the responses of individuals who exercise vigorously in hypoxic environments to better understand physiology at altitude and minimize the risk of deadly edema.
The other focus is epidemiology, the effects of hypoxia on lifespan and progression of cancer, heart disease, obesity, lung diseases, and neurological diseases, including Alzheimer’s and multiple sclerosis. Projected studies will investigate multiple sclerosis progression, longevity, cardiovascular disease, and behavior of malaria at altitude. Medical applications for these studies are being realized in conjunction with sophisticated geographic information systems technology that tracks migrations of populations.
I'm just speaking about Dr. Vollmer's research, Bob. He's the doctor who made the statement about CCSVI at ECTRIMS needing more research. He mentioned six negative studies (only 2 from ECTRIMS) and not the ten positive ones to come out of ECTRIMS from BNAC, Simka or Zamboni---Lyon wrote: and you seem to find it unfathomable that the vast majority of the medical establishment are capable, conscientious not owned by the pharmas....
Timothy Vollmer's Disclosures:
Grant/Research Support: Acorda Therapeutics, BioMS Medical, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Genentech, Genzyme Corp, Novartis, Ono Pharmaceuticals, PDL BioPharma, Pfizer, Inc., Sanofi-Aventis, Teva Neuroscience
Consultant/Scientific Boards: Biogen Idec, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Glaxo SmithKline, IMPAX, Novartis, Xeroport
Speaker’s Bureau/Speaking Honoraria: Athena Diagnostics, Biogen Idec, Teva Neuroscience